Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5122 | 1332-96-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 23, 2015 | FDA | ROCKWELL MEDICAL INC |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Iron supplement therapy | indication | 438911000124105 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 272MG IRON/PACKET | TRIFERIC | ROCKWELL MEDICAL INC | N208551 | April 25, 2016 | DISCN | POWDER | INTRAVENOUS | 7857977 | Sept. 8, 2027 | METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT |
| 27.2MG IRON/5ML (5.44MG IRON/ML) | TRIFERIC | ROCKWELL MEDICAL INC | N206317 | Jan. 23, 2015 | DISCN | SOLUTION | INTRAVENOUS | 7816404 | April 17, 2029 | METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT |
| 272MG IRON/PACKET | TRIFERIC | ROCKWELL MEDICAL INC | N208551 | April 25, 2016 | DISCN | POWDER | INTRAVENOUS | 7816404 | April 17, 2029 | METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT |
| 6.75MG IRON/4.5ML (1.5MG IRON/ML) | TRIFERIC AVNU | ROCKWELL MEDICAL INC | N212860 | March 27, 2020 | DISCN | SOLUTION | INTRAVENOUS | 7816404 | April 17, 2029 | METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY |
None
None
| ID | Source |
|---|---|
| UBY79OCO9G | UNII |
| 4034821 | VANDF |
| C4018308 | UMLSCUI |
| CHEBI:755915 | CHEBI |
| CHEMBL3833317 | ChEMBL_ID |
| 109374151 | PUBCHEM_CID |
| DB13995 | DRUGBANK_ID |
| 1607975 | RXNORM |
| 232967 | MMSL |
| 016429 | NDDF |
| 1802359-96-1 | SECONDARY_CAS_RN |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Triferic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57278-314 | SOLUTION | 5.44 mg | HEMODIALYSIS | NDA | 24 sections |
| Triferic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57278-315 | POWDER | 272 mg | INTRAVENOUS | NDA | 24 sections |
| Triferic AVNU | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57278-318 | SOLUTION | 1.50 mg | INTRAVENOUS | NDA | 24 sections |